Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer
Published: Oct 30, 2013
FLEMINGTON, N.J., Oct. 29, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced data from a preclinical study supporting further evaluation of its lead compound onapristone as a potential treatment for castration-resistant prostate cancer (CRPC). Results were presented during a poster session on Thursday, October 24 and in an oral presentation on Saturday, October 26 at the 20th Annual 2013 Prostate Cancer Foundation (PCF) Scientific Retreat, held October 24-26, 2013 in National Harbor, Md.
Help employers find you! Check out all the jobs and post your resume.